Navidea Biopharmaceuticals (NAVBQ)

Executive Summary

Navidea Biopharmaceuticals is a precision medicine company developing immuno-targeted diagnostics and therapeutics based on its Manocept platform, which targets the CD206 receptor on macrophages. The platform aims to improve detection and treatment of cancers, autoimmune disorders, and inflammatory conditions. Despite a robust pipeline including Lymphoseek (Phase 3, completed), Tc99m-tilmanocept (multiple Phase 1/2 trials), and [18F]NAV4694 for Alzheimer’s disease (Phase 2/3), the company has faced significant challenges. Many clinical trials have been completed, withdrawn, or terminated, and commercialization progress has been limited. With a current market valuation of approximately $10,000 and an OTC ticker (NAVBQ), the company appears to be in financial distress, lacking clear near-term revenue drivers. However, the underlying Manocept technology retains potential for partnering or licensing deals, and ongoing interest in CD206-targeted approaches could provide a path forward. The company’s ability to secure funding or strategic alliances is critical for its survival.

Upcoming Catalysts (preview)

• TBDPotential Partnership or Licensing Deal for Manocept Platform15% success
• Q4 2026Regulatory Update or New Trial Initiation for Tc99m-tilmanocept in Rheumatoid Arthritis10% success
• Q3 2026Restructuring or Reverse Merger Announcement20% success